Ablynx : ABLYNX TO PRESENT AT 2013 J.P. MORGAN HEALTHCARE CONFERENCE
GHENT, Belgium, 7 January 2013 - Ablynx [Euronext Brussels: ABLX] today
announces it will present at the 31^st Annual J.P. Morgan Healthcare
Conference in San Francisco, California on Thursday, 10^th January 2013 at
12:00 p.m. PST (21:00 p.m. CET).
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and
Chairman of Ablynx. The presentation will provide an update on the Company's
late-stage proprietary Nanobody® programmes, the Company's growth and
partnering strategy and the outlook for the near term future.
The presentation will be webcast live and can be accessed on the day via the
Ablynx website at www.ablynx.com. A replay of the webcast will be available on
the Company's website for 30 days following the presentation. To ensure a
timely connection, it is recommended that users register at least 10 minutes
prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at
clinical development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies including
Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is
headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
press release in pdf format
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Ablynx via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.